113707-75-8

Usage

Uses

Used in Pharmaceutical Industry:
(R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of biologically active molecules. Its chiral nature allows for the creation of enantiomerically pure compounds, which is crucial in drug discovery and development, as different enantiomers can exhibit distinct pharmacological properties.
Used in Agricultural Chemical Industry:
In the agricultural chemical sector, (R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester serves as a precursor in the production of agrochemicals, including pesticides and herbicides. Its unique structure and reactivity enable the synthesis of compounds with specific biological activities, contributing to the control of pests and weeds in agriculture.
Used in Research and Development:
(R)-(2-Iodo-1-methyl-ethyl)-carbamic acid benzyl ester is utilized as a research compound in academic and industrial laboratories. Its potential as a versatile building block makes it an attractive candidate for exploring new synthetic routes and developing novel molecules with potential applications in various fields, including medicine, materials science, and environmental chemistry.

Upstream product

• 113707-74-7 [(2R)-2-(benzyloxycarbonylamino)propyl] 4-methylbenzenesulfonate 
• 288-32-4 1H-imidazole 
• 61425-27-2 ((R)-2-hydroxy-1-methyl-ethyl)-carbamic acid benzyl ester 
• 603-35-0 triphenylphosphine 

Downstream Products

• 136522-02-6 (2S,5S)-2,5-dimethylpyrrolidine-1-carboxylic acid benzyl ester 
• 113774-91-7 ((R)-1-Methyl-pent-4-enyl)-carbamic acid benzyl ester 
• 142643-60-5 ((R)-1-Methyl-hex-5-enyl)-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Protease inhibitors

The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.

Protease inhibitors

The present invention provides C3-C6 1-amino-1-acyl cycloalkane-substituted 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K,

Protease inhibitors

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.

THE SYNTHESIS OF EITHER (+) OR (-) TRANS-2,5-DIMETHYLPYRROLIDINE

Trans-2,5-dimethylpyrrolidine, in either optical series, is prepared starting from D or L-alanine in an efficient and reasonably brief reaction sequence.